In conclusion, our study provides inaugural evidence that ARMC12/MYC-modulated transcriptional targets in NPC correlate with adverse clinical outcomes and function as critical drivers of NB pathogenesis. The gene discussed is ARMC12; the disease is neuroblastoma.